Q4 2025 Apyx Medical Inc Earnings Call Transcript
Key Points
- Apyx Medical Corp (APYX) reported a record revenue of $19.2 million for the fourth quarter, a significant increase from $14.2 million in the same period last year.
- Sales of the Aon body contouring system drove a 38% increase in the surgical aesthetics segment, reflecting strong market demand.
- The company successfully launched the Aon system, which integrates multiple functions, offering a comprehensive solution for body contouring.
- Apyx Medical Corp (APYX) has positioned itself to capitalize on the growing demand for treatments addressing skin laxity, particularly due to the rise in GLP-1 drug usage for weight loss.
- The company has implemented cost reduction and restructuring efforts, resulting in a leaner operating structure and reduced cash burn, strengthening its financial health.
- Despite the revenue growth, Apyx Medical Corp (APYX) reported a net loss attributable to stockholders of $1.3 million for the fourth quarter.
- Gross profit margin slightly decreased to 62.6% from 63% in the prior year period.
- The company anticipates a decrease in OEM segment sales for 2026, reflecting a strategic focus shift towards surgical aesthetics.
- Aon system sales are currently limited to the United States, with international expansion still in the early stages.
- The anticipated market clearance for the power liposuction feature of the Aon system is expected mid-2026, which could delay potential revenue from this enhancement.
Good morning, ladies and gentlemen, and welcome to the Apyx Medical fourth-quarter and full-year 2025 earnings conference call. (Operator Instructions)
I would now like to turn a conference call over to Jeremy Feffer, LifeSci Advisors. Please go ahead.
Thank you and welcome, everyone, to our fourth-quarter and full-year 2025 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx.
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the risk factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
